Clinical Trial Update: Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of panobinostat with bortezomib in pancreatic cancer progressing on gemcitabine has been terminated; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-08-26